The Pharmacomechanical Thrombectomy market is forecast to grow at a CAGR of 6.5%, reaching USD 2.6 billion in 2031 from USD 1.9 billion in 2026.
The pharmacomechanical thrombectomy is the process or technique through which the thrombus burden is diminished, using mechanical therapies and low-dose fibrinolysis. The global pharmacomechanical thrombectomy market is expected to witness major growth in the global market, majorly with the increasing global cases of thromboembolic diseases and shifting preference towards minimally invasive procedures. Similarly, the advancement in healthcare and medical technology is also expected to propel the growth of the global market, as with the increasing development in the sector, the efficacy and effectiveness of pharmacomechanical thrombectomy therapy are expected to rise.
The Pharmacomechanical Thrombectomy Market is witnessing a significant growth driven by two major factors
Increasing global prevalence of Thromboembolic diseases: The major factor propelling the growth of the global pharmacomechanical thrombectomy market is the increasing global prevalence of thromboembolic diseases, which includes ischemic strokes and deep vein thrombosis. The Centers for Disease Control and Prevention of the USA stated that in the nation, the annual cases of venous thromboembolism were recorded at about 900,000 annually.
Shifting preference towards minimally invasive procedures: The growing preferences for minimally invasive procedures are also expected to propel the growth of the market during the estimated timeline. The pharmacomechanical thrombectomy therapy system offers minimally invasive surgeries, resulting in faster recovery for the patients.
Pharmacomechanical Thrombectomy Market Segment Analysis by Product Type
Pharmacomechanical Devices: The pharmacomechanical devices category under the application segment is expected to grow at a greater rate compared to other types of devices in the market. The pharmacomechanical devices combine the thrombolytic agents with mechanical thrombectomy, which enhances the dissolution of clots.
Mechanical Thrombectomy Devices: The mechanical thrombectomy devices category is also expected to grow at a higher rate during the forecasted timeline. The mechanical thrombectomy devices feature devices, like stent retrievers and aspiration catheters, which physically remove clots.
Ultrasonic Thrombectomy Devices: The ultrasonic thrombectomy devices use the technology of ultrasound to dissolve clots, which can then be removed.
Pharmacomechanical Thrombectomy Market Segment Analysis by Application
Cardiovascular: The cardiovascular thrombectomy is a type of cardiac surgery that helps in removing the blood clots that are trapped in the veins and arteries of the body. In cardiovascular applications, the thrombectomy helps in the therapy for myocardial infection and peripheral artery disease.
Neurovascular: The neurology thrombectomy procedure commonly helps in the treatment of ischemic strokes, in which the clots from cerebral arteries are removed.
Peripheral Vascular: Peripheral vascular thrombectomy is a type of surgical treatment that helps in removing blood clots from the peripheral arteries.
Pharmacomechanical Thrombectomy Market Segment Analysis by Technology
Automated Devices: Under the technology segment of the pharmacomechanical thrombectomy market, the automated device category is expected to attain a greater market share. The automated device for thrombectomy offers enhanced performance with increased precision in clot removal.
Manual Devices: The manual device category in the application segment is also expected to grow at a higher rate during the forecasted timeline. The manual devices for thrombectomy require the precision of the operator for the removal of clots.
Pharmacomechanical Thrombectomy Market Segment Analysis by End-User
Hospitals: The hospital category in the end-user segment of the global pharmacomechanical thrombectomy market is expected to grow at a greater rate. The hospitals are among the major operators of the thrombectomy systems, with the availability of advanced treatment options, and wide area utilization of the system.
Ambulatory Surgical Centers: The share of ambulatory surgical centers in the pharmacomechanical thrombectomy market is also expected to grow significantly, as these centers offer specialized outpatient surgical procedures.
Others (research institute and rehabilitation center): The share of another category in the pharmacomechanical thrombectomy market is expected to attain a slower growth rate during the forecasted timeline. The thrombectomy devices offer limited application across research institutes and rehabilitation centers.
The pharmacomechanical thrombectomy market report analyzes growth factors across the following five regions:
North America: The North American region is expected to attain a greater market share in the global pharmacomechanical thrombectomy market, majorly with the increasing adoption of advanced medical technology and increasing consumer preference towards minimally invasive procedures. The increasing cases of thromboembolic diseases in the region are also witnessing significant growth, propelling the demand for the market.
Europe: The major factor propelling the growth of the pharmacomechanical thrombectomy market in the European region is the increasing advancement in medical technology in the region. With the introduction of favorable governmental policies in the healthcare sector, the market is expected to grow.
Asia Pacific: The Asia Pacific region is among the fastest emerging regions in the healthcare sector, which is expected to grow at a greater rate in the global pharmacomechanical thrombectomy market during the forecasted timeline. The increasing investment and introduction of governmental policies to boost the healthcare sector are among the key factors boosting the growth of the market.
South America & MEA: Increasing innovations and development in the healthcare sector are among the key factors driving the growth of the global pharmacomechanical thrombectomy market in the South American region and the Middle East & African region.
Boston Scientific Corporation: With the AngioJet system, which combines active aspiration and Power PulseTM technology to efficiently treat a variety of thrombosed arteries, the company leads the pharmacomechanical thrombectomy market.
Abbott: The company concentrates on creating cutting-edge thrombectomy solutions, using its knowledge of vascular interventions to improve patient outcomes using cutting-edge technologies and minimally invasive clot removal techniques.
Medtronic plc: One of the biggest players in the thrombectomy market, with devices for fast clot removal and restoration of blood flow, while keeping patient safety and effectiveness at the forefront of vascular procedures.
Inari Medical, Inc.: Specializes in advanced thrombectomy devices that employ a novel technique to remove blood clots, focusing on improving patient outcomes while reducing the risks associated with conventional procedures.
These companies are the leaders in the development and production of pharmacomechanical thrombectomy systems and also contribute extensively to innovation and development in the healthcare sector.
In September 2024, Vesalio Inc., an American-based medical device leader, announced the launch of the pVasc Thrombectomy system for peripheral occlusion in the US market. The system features the non-surgical removal capability of peripheral occasions.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Companies |
|
By Product Type
Pharmacomechanical Devices
Mechanical Thrombectomy Devices
Ultrasonic Thrombectomy Devices
By Application
Cardiovascular
Neurovascular
Peripheral Vascular
By Technology
Automated Devices
Manual Devices
By End-User
Hospitals
Ambulatory Surgical Centers
Others
By Geography
North America
Europe
Asia Pacific
South America
Middle East & Africa